share_log

Plus Therapeutics' Phase 2b Trial of Rhenium to Treat Recurrent Glioblastoma Doses First Patient

Plus Therapeutics' Phase 2b Trial of Rhenium to Treat Recurrent Glioblastoma Doses First Patient

Plus Therapeutics的用于治疗复发性胶质母细胞瘤剂量的Rhenium的2b期试验首例患者
MT Newswires ·  2023/01/18 20:52

Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发